CONVERTING ENZYME-INHIBITORS AND RENAL-FUNCTION IN ESSENTIAL AND RENOVASCULAR HYPERTENSION

被引：19

作者：

MIMRAN, A

RIBSTEIN, J

DUCAILAR, G

机构：

[1] Department of Medicine, Centré Hospitalier Universitaire

[2] Department of Medicine, Centre, Hospitalier Universitaire, Montpellier

[3] Department of Planning Coordination for Scientific Affairs, Pharmaceutical Affairs, Takeda Chemical, Chuo-ku, Osaka, 541, 3-b

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1991年 / 4卷 / 01期

关键词：

CONVERTING ENZYME INHIBITORS; HYPERTENSION; RENAL FUNCTION; KALLIKREIN; RENAL FAILURE;

D O I：

10.1093/ajh/4.1.7S

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Converting enzyme inhibitors (CEI) are useful in the treatment of hypertension. However, acute renal deterioration may occur in some conditions in association with the crucial role of angiotensin in the regulation of glomerular filtration rate (GFR), such as volume depletion, severe stenosis of both renal arteries, and stenosis of a single functioning kidney. CEI-induced acute renal failure can develop in the absence of a fall in systemic pressure, is facilitated by prior sodium depletion, and is reversible upon discontinuation of treatment. In a personal study conducted in 28 patients with CEI-induced renal dysfunction (reversible after discontinuation of CEI), the incidence of stenosis of large renal vessels was 61%, whereas 39% of these subjects had no significant renal artery abnormalities. Although the occurrence of such a complication is not a convincingly accurate predictor of the existence of renovascular hypertension, angiographic detection of renal artery stenosis (bilateral or on a single-functioning kidney) may be justified in some of these patients.

引用

页码：S7 / S14

页数：8

共 31 条

[1]

Anderson S., Rennke H.G., Brenner B.M., Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat, J Clin Invest, 77, pp. 1993-2000, (1986)

[2]

Mimran A., Brunner H.R., Turini G.A., Et al., Effect of capto-pril on renal vascular tone in patients with essential hypertension, Clin Sci, 57, pp. 421S-423S, (1979)

[3]

Hollenberg N.K., Meggs L.G., Williams G.H., Et al., Sodium intake and renal responses to captopril in normal man and in essential hypertension, Kidney Int, 20, pp. 240-245, (1981)

[4]

Dluhy R.G., Smith K., Taylor T., Et al., Prolonged converting-enzyme inhibition in non-modulating hypertension, Hypertension, 13, pp. 371-377, (1989)

[5]

Redgrave J., Rabinowe S., Hollenberg N.K., Williams G.H., Correction of abnormal renal blood flow response to angiotensin by converting enzyme inhibition in essential hypertensives, J Clin Invest, 75, pp. 1285-1290, (1985)

[6]

Dluhy R.G., Hopkins P., Hollenberg N.K., Et al., Heritable abnormalities of the renin-angiotensin system in essential hypertension, J Cardiovasc Pharmacol, 12, pp. 149-154, (1988)

[7]

Uneda S., Fujishima S., Fujiki Y., Et al., Renal hemodynamics and the renin-angiotensin system in adolescents genetically predisposed to essential hypertension, J Hypertension, 2, pp. 437-739, (1984)

[8]

Bauer J.H., Role of angiotensin converting enzyme inhibitors in essential and renal hypertension, Am J Med, 77, 2, pp. 43-51, (1984)

[9]

O'connor D.T., Mosley C.A., Cervenka J., Bernstein K.N., Contrasting renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension, J Hypertens, 2, pp. 89-92, (1984)

[10]

Madeddu P., Oppes M., Rubattu S., Et al., Role of renal kallikrein in modulating the antihypertensive effect of a single oral dose of captopril in normal and low-renin essential hypertensives, J Hypertens, 5, pp. 645-648, (1987)

← 1 2 3 4 →